Filing Details

Accession Number:
0000950170-24-038530
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-29 14:12:35
Reporting Period:
2024-03-27
Accepted Time:
2024-03-29 14:12:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1088856 Corcept Therapeutics Inc CORT Pharmaceutical Preparations (2834) 770487658
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1698310 Sean Maduck C/O Corcept Therapeutics Incorporated
149 Commonwealth Drive
Menlo Park CA 94025
See Remarks No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-03-27 25,953 $3.88 111,175 No 4 M Direct
Common Stock Disposition 2024-03-27 25,953 $25.01 85,222 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock option (right to buy) Disposition 2024-03-27 25,953 $0.00 25,953 $3.88
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
91,986 2026-02-26 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 10,000 Indirect See Footnote
Common Stock 10,000 Indirect See Footnote
Footnotes
  1. Includes 1,658 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, 456 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 582 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 636 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. The transaction was made pursuant to a 10b5-1 plan in effect at the time of this transaction.
  3. Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
  4. Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
  5. Fully exercisable.